PROCEPT BioRobotics Corporation Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
22 9월 2021 - 5:05AM
PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (“PROCEPT”), a
commercial-stage surgical robotics company focused on advancing
patient care by developing transformative solutions in urology,
today announced the closing of its upsized initial public offering
of 7,539,400 shares of its common stock, including the full
exercise of the underwriters’ option to purchase up to 983,400
additional shares of common stock, at a public offering price of
$25.00 per share. All of the shares were offered by PROCEPT. The
gross proceeds from the offering, before deducting underwriting
discounts and commissions and other offering expenses, were
approximately $188.5 million. The shares began trading on the
Nasdaq Global Market on September 15, 2021 under the ticker symbol
"PRCT."
BofA Securities and Goldman Sachs & Co. LLC acted as joint
lead bookrunning managers for the offering. Cowen, Guggenheim
Securities and SVB Leerink acted as co-managers.
Registration Statements relating to the shares being sold in
this offering became effective on September 14, 2021. The
offering was made only by means of a prospectus, copies of which
may be obtained from BofA Securities, NC1-004-03-43, 200 North
College Street, 3rd Floor, Charlotte, NC 28255-0001, Attention:
Prospectus Department, or by email at
dg.prospectus_requests@bofa.com; or Goldman Sachs & Co. LLC,
Attention: Prospectus Department, 200 West Street, New York, NY
10282, by telephone at (866) 471-2526, or by email at
Prospectus-ny@ny.email.gs.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or other jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of
any such state or other jurisdiction.
About PROCEPT BioRobotics CorporationPROCEPT is
a commercial-stage surgical robotics company focused on advancing
patient care by developing transformative solutions in urology.
PROCEPT develops, manufactures and sells the AquaBeam Robotic
System, an advanced, image-guided, surgical robotic system for use
in minimally-invasive urologic surgery with an initial focus on
treating benign prostatic hyperplasia, or BPH. BPH is the most
common prostate disease and impacts approximately 40 million men in
the United States. PROCEPT designed Aquablation therapy to deliver
effective, safe and durable outcomes for males suffering from lower
urinary tract symptoms, or LUTS, due to BPH that are independent of
prostate size and shape or surgeon experience. PROCEPT has
developed a significant and growing body of clinical evidence,
which includes nine clinical studies and over 100 peer-reviewed
publications, supporting the benefits and clinical advantages of
Aquablation therapy.
Investor Contact:Gilmartin GroupMatt Bacso,
CFAMatt.bacso@gilmartinir.com
PROCEPT BioRobotics (NASDAQ:PRCT)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
PROCEPT BioRobotics (NASDAQ:PRCT)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024